Tobira Therapeutics Inc (TBRA) was Initiated by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $22. H.C. Wainwright advised their investors in a research report released on Apr 11, 2016.
Tobira Therapeutics Inc closed down -0.02 points or -0.27% at $7.28 with 2,28,714 shares getting traded on Monday. Post opening the session at $7.82, the shares hit an intraday low of $6.8111 and an intraday high of $7.99 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Tobira Therapeutics Inc. formerly Regado BioSciences Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat liver disease inflammation fibrosis and human immunodeficiency virus (HIV). The Companys lead product candidate cenicriviroc (CVC) is an immunomodulator that can be used to treat a number of diseases including non-alcoholic steatohepatitis (NASH) kidney fibrosis HIV-1 and others. The Company is engaged in clinical studies for CVC including the CENTAUR Study an international randomized Phase IIb study of CVC and placebo in patients with NASH and liver fibrosis (NCT02217475). The Company has initiated ORION a Phase IIa Study of Cenicriviroc in obese patients with fatty liver disease. It is also engaged in the Phase I pioglitazone safety combination study. NASH is a type of non-alcoholic fatty liver disease or NAFLD. NAFLD is a liver disease and is associated with obesity and type-2 diabetes.